Ganymed raises €65 million
This article was originally published in Scrip
Executive Summary
Ganymed, a German cancer antibody discovery company, has raised €65 million to develop its antibody pipeline. The company's lead antibody, the monoclonal claudiximab (iMAB362), will enter a multicentre Phase Ib study for metastatic gastroesophageal carcinoma later this year. A further five antibodies are in preclinical development for breast, colorectal, lung, pancreatic and prostate cancers. The round was led by Munich-based ATS Beteiligungsverwaltung and joined by Future Capital AG, MIG Verwaltungs AG and private investors.